Minimally Invasive Radical Hysterectomy Using Endoscopic Stapler in Stage IB2 or IIA1 Cervical Cancer

NCT ID: NCT07256977

Last Updated: 2025-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

494 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2035-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter, open-label, non-inferiority, randomized controlled, investigator-initiated clinical trial comparing the efficacy and safety of open radical hysterectomy versus minimally invasive radical hysterectomy using an endoscopic stapler as surgical treatments for early cervical cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study exclusively includes patients with stage IB2 or IIA1 cervical cancer who have tumors measuring 2 cm or larger but less than 4 cm. After randomization, one group undergoes radical hysterectomy via open surgery, while the other group undergoes minimally invasive radical hysterectomy using an endoscopic stapler. This approach using an endoscopic stapler aims to prevent intraoperative exposure of tumor cells to the abdominal cavity, comparable to open surgery, thereby enabling a comparison of therapeutic efficacy and safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer Stage IB2 Cervical Cancer Stage IIa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open radical hysterectomy

Radical hysterectomy is performed via open surgery

Group Type EXPERIMENTAL

Open radical hysterectomy

Intervention Type DEVICE

Radical hysterectomy is performed via open surgery, and Wertheim clamp is used for preventing tumor spillage during colpotomy

Minimally invasive radical hysterectomy

Radical hysterectomy is performed via minimally invasive surgery

Group Type EXPERIMENTAL

Minimally invasive radical hysterectomy

Intervention Type DEVICE

Radical hysterectomy is performed via minimally invasive surgery, and an endoscopic stapler is used for preventing tumor spillage during colpotomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Open radical hysterectomy

Radical hysterectomy is performed via open surgery, and Wertheim clamp is used for preventing tumor spillage during colpotomy

Intervention Type DEVICE

Minimally invasive radical hysterectomy

Radical hysterectomy is performed via minimally invasive surgery, and an endoscopic stapler is used for preventing tumor spillage during colpotomy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 2018 FIGO stage IB2 or IIA1 cervical cancer (tumor maximum diameter ≥2 cm and \<4 cm)
2. Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
3. Planned for Type B or C radical hysterectomy
4. With adequate bone marrow, renal, and hepatic function

* WBC \>3.0 × 10⁹ cells/L
* Platelets \>100 × 10⁹ cells/L
* Creatinine \<180 μmol/L
* Bilirubin \<1.5 × normal range
* AST, ALT \< 3 × normal range
5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
6. Previous history of other invasive malignancies with no evidence of recurrence for at least 5 years
7. Signed and approved consent form

Exclusion Criteria

1. Histological types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
2. Tumor size less than 2 cm classified as 2018 FIGO stage IA1, IA2, or IB1 disease
3. The following are observed on preoperative CT or MRI

* Tumor size ≥4 cm
* Lymph node metastasis (short axis ≥15 mm)
* Paracervical invasion
* Bladder or rectal invasion
* Distant metastasis
4. Prior pelvic or abdominal radiotherapy
5. Prior neoadjuvant chemotherapy before surgery
6. Unsuitable for surgery due to severe systemic disease at the investigator's discretion
7. Difficult to consider intraoperative lymphatic mapping due to

* Allergy to triphenylmethane compounds
* History of prior retroperitoneal surgery
* History of prior pelvic radiotherapy
* Cases where cold knife or loop electrosurgical excision procedure (LEEP) was performed within 4 weeks prior to study participation
* Allergy to triphenylmethane compounds
Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ajou University School of Medicine

OTHER

Sponsor Role collaborator

SMG-SNU Boramae Medical Center

OTHER

Sponsor Role collaborator

Konkuk University

OTHER

Sponsor Role collaborator

DongGuk University

OTHER

Sponsor Role collaborator

Keimyung University

OTHER

Sponsor Role collaborator

National Cancer Center, Korea

OTHER_GOV

Sponsor Role collaborator

The Catholic University of Korea

OTHER

Sponsor Role collaborator

Wonju Severance Christian Hospital

OTHER

Sponsor Role collaborator

Kangbuk Samsung Hospital

OTHER

Sponsor Role collaborator

Asan Medical Center

OTHER

Sponsor Role collaborator

Samsung Medical Center

OTHER

Sponsor Role collaborator

Sinchon Severance Hospital, Yonsei University College of Medicine

UNKNOWN

Sponsor Role collaborator

Seoul National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hee Seung Kim

Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University College of Medicine

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hee Seung Kim, Professor

Role: CONTACT

82-2-2072-4863

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hee Seung Kim

Role: primary

82-2-2072-4863

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0620202330

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

SOLUTION2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.